| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/20/2003 | US20030035796 Novel compound for treatment of allergy and asthma |
| 02/20/2003 | US20030035793 Novel immune response targeting molecules |
| 02/20/2003 | US20030035792 Recombinant MVA virus, and the use thereof |
| 02/20/2003 | US20030035790 Anticancer agents, antinflamamtory agents, infection therapy |
| 02/20/2003 | CA2763913A1 Antigen binding domains |
| 02/20/2003 | CA2467919A1 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 02/20/2003 | CA2459071A1 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma |
| 02/20/2003 | CA2457400A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 02/20/2003 | CA2457349A1 Sub-unit vaccine for infectious pancreatic necrosis virus |
| 02/20/2003 | CA2457322A1 Process for the maturation of dentritic cells and a vaccine |
| 02/20/2003 | CA2456802A1 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 02/20/2003 | CA2456723A1 Inhibitors of her3 activity |
| 02/20/2003 | CA2456607A1 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | CA2456369A1 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | CA2456328A1 Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof |
| 02/20/2003 | CA2456295A1 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 02/20/2003 | CA2456247A1 Use of il-18 inhibitors in hypersensitivity disorders |
| 02/20/2003 | CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454251A1 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453248A1 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/20/2003 | CA2452488A1 Electrodes coated with treating agent and uses thereof |
| 02/20/2003 | CA2428822A1 Modulators of p-selectin glycoprotein ligand 1 |
| 02/19/2003 | EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof |
| 02/19/2003 | EP1284144A1 Anti-tumor vaccines |
| 02/19/2003 | EP1284137A1 Nonoral preparation having three-layer structure |
| 02/19/2003 | EP1283887A1 Chimeric arterivirus-like particles |
| 02/19/2003 | EP1283885A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/19/2003 | EP1283882A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/19/2003 | EP1283869A2 Novel bee venom polypeptides and methods of use thereof |
| 02/19/2003 | EP1283851A2 Use of interleukin-4 antagonists and compositions thereof |
| 02/19/2003 | EP1283848A2 Protein complexes and assays for screening anti-cancer agents |
| 02/19/2003 | EP1283726A2 Dendritic cells loaded with toxic substances |
| 02/19/2003 | EP1283722A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| 02/19/2003 | EP1283721A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/19/2003 | EP1283720A1 Recombinant or purified polyclonal antibodies for treating allergy |
| 02/19/2003 | EP1283719A2 Apoptotic agents |
| 02/19/2003 | EP1283718A2 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 02/19/2003 | EP1283716A1 Vaccine comprising a tick cement protein |
| 02/19/2003 | EP0950065B1 Peptide as diagnostic and therapeutic agent for autoimmune diseases |
| 02/19/2003 | EP0793484B1 Adjuvant for a vaccine composition |
| 02/19/2003 | EP0699237B1 Anti-egfr single-chain fvs and anti-egfr antibodies |
| 02/19/2003 | EP0661980B1 Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| 02/19/2003 | CN1398297A Recombinant flaviviruses and methods of use thereof |
| 02/19/2003 | CN1398189A Combination therapy of radiation and COX-2 inhibitor for treatment of neoplasia |
| 02/19/2003 | CN1398188A Boltuminum toxin pharmaceutical compsns |
| 02/19/2003 | CN1398187A Method and compsns. for treating liver cell cancer |
| 02/19/2003 | CN1397639A Cholera vibrio strain |
| 02/19/2003 | CN1397346A Genetically engineered rabies virus vaccine with recombination-defective adenovirus carrier |
| 02/18/2003 | US6521776 Immunological adjuvant compounds compositions and methods of use thereof |
| 02/18/2003 | US6521749 GL50 nucleic acids and uses therefor |
| 02/18/2003 | US6521746 Leukotoxin polypeptide fused to gonadotropin releasing hormone/factor multimer; increased immunogenicity |
| 02/18/2003 | US6521745 Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| 02/18/2003 | US6521741 Catalytic antibodies and a method of producing same |
| 02/18/2003 | US6521598 Peptide consisting of an amino acid sequence 1: SPSVDKARAEL; induces transplant tolerance |
| 02/18/2003 | US6521593 Using antagonists of integrins such as alpha v beta 3 and alpha v beta 5; inhibiting angiogenesis and vitronectin and tenascin mediated cell adhesion; inducing apoptosis |
| 02/18/2003 | US6521457 Lentivirus-based gene transfer vectors |
| 02/18/2003 | US6521453 Oligonucloetide mediated nucleic acid recombination |
| 02/18/2003 | US6521441 Staphylococcus aureus genes and polypeptides |
| 02/18/2003 | US6521437 Human sphingosine lyase polypeptides |
| 02/18/2003 | US6521436 Gene expression; drug screening for antiarthritic agents; bone disorders |
| 02/18/2003 | US6521423 Intracellular production of Hepatitis C E2 polypeptides |
| 02/18/2003 | US6521422 Fhm, a novel member of the TNF ligand supergene family |
| 02/18/2003 | US6521415 Tandem immuno-assay for cancer |
| 02/18/2003 | US6521412 Drug screening for anticarcinogenic agents and agents to treat atherosclerosis and neurodegenerative disorders |
| 02/18/2003 | US6521236 Vector vaccine of recombinant feline herpesvirus |
| 02/18/2003 | US6521231 Pseudorabies virus protein |
| 02/18/2003 | US6521230 CD25 binding molecules |
| 02/18/2003 | US6521229 41 kDa Cryptosporidium parvum oocyst wall protein |
| 02/18/2003 | US6521227 Monoclonal or polyclonal antibodies having preferential binding to polypeptides used as prostate specific antigens |
| 02/18/2003 | CA2130072C Method of detecting a pathogen using a virus |
| 02/18/2003 | CA2100591C Avirulent anti-rabies vaccine |
| 02/18/2003 | CA2075366C Immunologically active peptides or polypeptides from the parvovirus b19 |
| 02/17/2003 | CA2356390A1 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
| 02/15/2003 | CA2392305A1 Adrenic acid receptor and uses thereof |
| 02/13/2003 | WO2003012441A1 Method for detecting modulators of notch signalling |
| 02/13/2003 | WO2003012432A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 02/13/2003 | WO2003012395A2 Early detection of mycobacterial disease using peptides |
| 02/13/2003 | WO2003012107A1 Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof |
| 02/13/2003 | WO2003012105A2 Vegf isoform |
| 02/13/2003 | WO2003012093A2 Regulator of calcineurin |
| 02/13/2003 | WO2003012086A1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 02/13/2003 | WO2003012085A1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 02/13/2003 | WO2003012075A1 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012048A2 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof |
| 02/13/2003 | WO2003011909A1 Binding agents with differential activity |
| 02/13/2003 | WO2003011907A2 Receptor, the use thereof, and mouse antibodies |
| 02/13/2003 | WO2003011903A2 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 02/13/2003 | WO2003011902A1 Identification of specific tumour antigens by selection of cdna libraries with sera |
| 02/13/2003 | WO2003011899A2 Antigenic polypeptides |
| 02/13/2003 | WO2003011898A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 02/13/2003 | WO2003011893A2 Immunologically significant herpes simplex virus antigens and methods for using same |
| 02/13/2003 | WO2003011878A2 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 02/13/2003 | WO2003011345A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | WO2003011342A2 Targeted polymeric delivery systems |
| 02/13/2003 | WO2003011336A2 Liposomes prepared from the extractable lipids from a mycobacterium |
| 02/13/2003 | WO2003011335A2 Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
| 02/13/2003 | WO2003011334A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |